Comparison of lidoflazine and quindine in prophylactic treatment of arrhythmias.
The efficacy of quinidine versus lidoflazine therapy was compared in the maintenance of sinus rhythm after electrical cardioversion for atrial flutter or fibrillation in a group of 35 patients. Both quinidine and lidoflazine were relatively ineffective in maintaining sinus rhythm after cardioversion. Lidoflazine was also used to prevent supraventricular and ventricular tachycardias in a miscellaneous group of patients; one of these with paroxysmal supraventricular tachycardia developed runs of venttricular tachycardia soon after starting lidoflazine. The trial was stopped after 4 patients died while receiving lidoflazine, on the suspicion that their deaths may have been related to drug-induced arrhythmias. The arrhythmogenic potential of lidoflazine when used in patients with supraventricular arrhythmias constrasts with reports of its apparent safety in large numbers of patients with angina pectoris.
D000328:Adult; D000368:Aged; D001281:Atrial Fibrillation / Q000517:prevention & control*; D001282:Atrial Flutter / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D003645:Death, Sudden; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004554:Electric Countershock; D004562:Electrocardiography; D005260:Female; D006801:Humans; D008013:Lidoflazine / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011802:Quinidine / Q000627:therapeutic use*
D010879:Piperazines; D011802:Quinidine; D008013:Lidoflazine